Introduction Metabolic-associated steatohepatitis (MASH) represents a significant health burden worldwide
Evidence from the Major Clinical Trials The safety information for these treatments comes from extensive clinical research, including the STEP program for Semaglutide and the SURMOUNT trials for Tirzepatide
Over time, it can become an integral part of a comprehensive health plan that may include diet modification , regular physical activity , and monitoring of blood glucose levels
Research by Raun et al
These drugs help reduce hunger and promote a feeling of fullness, making it easier for individuals to manage calorie intake while maintaining a healthy diet
References Chang, C.H., Tsai, W.C., Lin, M.S., Hsu, Y.H., Pang, J.H